Alimera Sciences
http://alimerasciences.com/Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera”), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Our lead product is ILUVIEN, now approved for marketing in the U.S. and 15 European countries for the treatment of diabetic macular edema.
Phone: +1 678-990-5740
Investors 3
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| 07.08.2021 | New Enterp... | nea.com |
| - | Sofinnova ... | sofinnova.... |
Mentions in press and media 7
| Date | Title | Description | Category | Author | Source |
| 14.04.2021 | ALIMERA SC... | Alimera grants exclusive licen... | - | - | marketscre... |
| 14.04.2021 | Alimera Sc... | Alimera Sciences, Inc. (Nasdaq... | - | - | marketscre... |
| 18.02.2014 | Alimera ra... | Alimera Sciences (NSDQ:ALIM) r... | - | Arezu Sarv... | massdevice... |
| 03.10.2012 | Biotech co... | Solution/Product: The company ... | - | - | medcitynew... |
| 23.04.2010 | Morning Re... | Why people hate insurance comp... | - | - | medcitynew... |
| 18.03.2008 | Life-scien... | TODAY’S HEADLINES: Luminous Me... | - | - | venturebea... |
| 17.01.2008 | Life scien... | TODAY’S HEADLINES: TransEnter... | - | - | venturebea... |